Actively Recruiting
Observational Registry Study Monitoring LEQEMBI Use in Alzheimers Disease Patients in Canada
Led by Eisai Limited · Updated on 2026-10-13
400
Participants Needed
17
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a noninterventional, prospective observational study in Canada to monitor participants with Alzheimers Disease who are treated with LEQEMBI during routine clinical practice. The study aims to describe the occurrence and severity of known side effects, including brain imaging abnormalities and intracerebral hemorrhages, and analyze these according to genetic factors, other medications, and baseline brain scans. Additionally, the study will observe the progression of Alzheimers Disease and identify any previously unknown side effects related to LEQEMBI. Participants in this registry study are those prescribed LEQEMBI and will be observed without any experimental treatment or intervention. The study collects data on drug use, adverse events, disease progression, and the effectiveness of safety measures over a period of up to three years. There is no active treatment administered by the study, and information is gathered during routine medical care. During the study, participants will have their health monitored through regular clinical practice assessments. Researchers will track side effects, disease progression, treatment duration, and drug utilization. Data on serious adverse reactions, treatment discontinuations, and deaths within 30 days of stopping LEQEMBI will also be collected. The study will last up to three years with ongoing observation to evaluate the safety and outcomes associated with LEQEMBI use.
CONDITIONS
Brief Title
A Post Authorization Registry Study of Participants Treated With LEQEMBI
Research Team
E
Eisai Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here